Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, prospective observation post-authorisation, open-label study of sublingual fentanyl tablets for relief of breakthrough pain in cancer patients and association with quality of life outcomes

Trial Profile

A multicentre, prospective observation post-authorisation, open-label study of sublingual fentanyl tablets for relief of breakthrough pain in cancer patients and association with quality of life outcomes

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jun 2019 Results of sub-group analysis of two categories [patients aged between 65 and 74 years (low age group) and patients aged 75 years and over (high age group)] assessing efficacy and tolerability of Fentyl sublingual tablets in cancer pain patients, published in the Drugs in R and D.
    • 31 Jul 2017 New trial record
    • 25 Jul 2017 Results of subgroup (age more than or equal to 65 years and less than 65 years) analysis published in the Drugs in R and D
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top